Abstract
Prodrugs are inactive compounds which are metabolized either chemically or enzymatically in a controlled or predictable manner to the parent active drug inside the body. Prodrugs can enhance the therapeutic efficacy and/or reduce adverse effects via different mechanisms, including increased solubility, improved permeability and bioavailability, prolonged half-life, and tissue-targeted delivery. Besides the prodrug itself, optimization of vehicles and other enhancement techniques is important as well. Strategies to improve the oral bioavailability and achieve tumor-specific targeting have been the most important developments in prodrug design during the last 5 years. This review describes recent developments in orally administered and tumor-targeted prodrugs. Pharmacokinetic and pharmacodynamic evaluations of these prodrugs are systematically introduced in this review.
Keywords: Prodrug, oral administration, anticancer drug, pharmacokinetics, pharmacodynamics
Current Pharmaceutical Design
Title: Current Prodrug Design for Drug Discovery
Volume: 15 Issue: 19
Author(s): Pei-Wen Hsieh, Chi-Feng Hung and Jia-You Fang
Affiliation:
Keywords: Prodrug, oral administration, anticancer drug, pharmacokinetics, pharmacodynamics
Abstract: Prodrugs are inactive compounds which are metabolized either chemically or enzymatically in a controlled or predictable manner to the parent active drug inside the body. Prodrugs can enhance the therapeutic efficacy and/or reduce adverse effects via different mechanisms, including increased solubility, improved permeability and bioavailability, prolonged half-life, and tissue-targeted delivery. Besides the prodrug itself, optimization of vehicles and other enhancement techniques is important as well. Strategies to improve the oral bioavailability and achieve tumor-specific targeting have been the most important developments in prodrug design during the last 5 years. This review describes recent developments in orally administered and tumor-targeted prodrugs. Pharmacokinetic and pharmacodynamic evaluations of these prodrugs are systematically introduced in this review.
Export Options
About this article
Cite this article as:
Hsieh Pei-Wen, Hung Chi-Feng and Fang Jia-You, Current Prodrug Design for Drug Discovery, Current Pharmaceutical Design 2009; 15 (19) . https://dx.doi.org/10.2174/138161209788682523
DOI https://dx.doi.org/10.2174/138161209788682523 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Targeting 5-Lipoxygenase for Prevention and Treatment of Cancer
Current Enzyme Inhibition Impact of Oncogenic Protein Tyrosine Phosphatases in Cancer
Anti-Cancer Agents in Medicinal Chemistry Key Questions in Metastasis: New Insights in Molecular Pathways and Therapeutic Implications
Current Pharmaceutical Biotechnology Immunotherapy in Bladder Cancer
Current Molecular Pharmacology Lipids at the Cross-road of Autoimmunity in Multiple Sclerosis
Current Medicinal Chemistry Involvement of Nucleotide Excision and Mismatch Repair Mechanisms in Double Strand Break Repair
Current Genomics Rate-Determining and Rate-Limiting Steps in the Clearance and Excretion of a Potent and Selective p21-Activated Kinase Inhibitor: A Case Study of Rapid Hepatic Uptake and Slow Elimination in Rat
Drug Metabolism Letters Current Biomarkers for Lung Cancer
Current Signal Transduction Therapy Receptor Mediated Tumor Targeting: An Emerging Approach for Cancer Therapy
Current Drug Delivery New Approaches in Glioblastoma Multiforme: The Potential Role of Immune- check Point Inhibitors
Current Cancer Drug Targets In-Situ Hybridization as a Molecular Tool in Cancer Diagnosis and Treatment
Current Medicinal Chemistry Involvement of Cysteine Proteases in Cancer
Current Medicinal Chemistry Development of RGD-Based Radiotracers for Tumor Imaging and Therapy: Translating from Bench to Bedside
Current Molecular Medicine Cancer Preventive Phytochemicals as Speed Breakers in Inflammatory Signaling Involved in Aberrant COX-2 Expression
Current Cancer Drug Targets Diagnosis and Management of Endocrine Hypertension in Children and Adolescents
Current Pharmaceutical Design Application of Nanotechnology in the Treatment and Diagnosis of Gastrointestinal Cancers: Review of Recent Patents
Recent Patents on Anti-Cancer Drug Discovery The Role of ABC Transporters in Protecting Cells from Bilirubin Toxicity
Current Pharmaceutical Design Targeting Cancer Cells by an Oxidant-Based Therapy
Current Molecular Pharmacology Risk Factors for Lung Cancer in Never Smokers: A Recent Review Including Genetics
Current Respiratory Medicine Reviews Ocular Inflammatory Diseases: Molecular Pathogenesis and Immunotherapy
Current Molecular Medicine